In cancer, both intrinsic and therapeutic mechanisms require efficient DC-mediated cross-presentation of tumor antigens to CD8+ T cells to achieve effective anti-tumor immunity (Barber et al., 2006; Barry et al., 2018; Chen and Mellman, 2013; Garris et al., 2018; Jansen et al., 2019; Spranger et al., 2016). The gene discussed is CD8A; the disease is neoplasm.